Holen Sie sich die Stockscreener-App
7.30
6.05%
-0.47
Handel nachbörslich:
7.44
0.14
+1.92%
Schlusskurs vom Vortag:
$7.77
Offen:
$7.7
24-Stunden-Volumen:
973.22K
Relative Volume:
0.99
Marktkapitalisierung:
$417.09M
Einnahmen:
$20.72M
Nettoeinkommen (Verlust:
$-100.84M
KGV:
-2.7444
EPS:
-2.66
Netto-Cashflow:
$-78.56M
1W Leistung:
-2.67%
1M Leistung:
-34.12%
6M Leistung:
+72.99%
1J Leistung:
+25.00%
1-Tages-Spanne:
$7.20
$7.715
1-Wochen-Bereich:
$6.96
$8.06
52-Wochen-Spanne:
$2.235
$12.34
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Firmenname
4 D Molecular Therapeutics Inc
Sektor
Branche
Telefon
(510) 505-2680
Adresse
5858 HORTON STREET #455, EMERYVILLE
Vergleichen Sie FDMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
7.30 | 443.94M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-07 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2025-01-13 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Underweight |
| 2024-09-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | Eingeleitet | Barclays | Overweight |
| 2024-02-07 | Fortgesetzt | Goldman | Buy |
| 2023-10-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-18 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-11-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-11-15 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-12 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | Eingeleitet | Jefferies | Buy |
| 2022-01-04 | Eingeleitet | SVB Leerink | Outperform |
| 2021-01-05 | Eingeleitet | BofA Securities | Buy |
| 2021-01-05 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-05 | Eingeleitet | Goldman | Neutral |
Alle ansehen
4 D Molecular Therapeutics Inc Aktie (FDMT) Neueste Nachrichten
Can 4D Molecular Therapeutics Inc. stock double in next 5 yearsJuly 2025 Institutional & Risk Controlled Swing Alerts - ulpravda.ru
Is 4D Molecular Therapeutics Inc. stock a buy on dipsJuly 2025 Setups & Free Long-Term Investment Growth Plans - ulpravda.ru
Is 4D Molecular Therapeutics Inc. stock a top momentum play2025 Volatility Report & High Accuracy Swing Trade Signals - ulpravda.ru
Will 4D Molecular Therapeutics Inc. stock gain from strong economyPrice-to-Book Ratio Updates & Budget Friendly Portfolio Growth - ulpravda.ru
4D Molecular Therapeutics, Inc. Announces Executive Changes - MarketScreener
4DMT Provides Company Update and Anticipated Development Milestones for 2026 - The Manila Times
2026 world cup analysis rankings: Will 4D Molecular Therapeutics Inc. stock gain from strong economy2026 world cup usa national team round of 32 defensive leaders counter attacking winner prediction expert opinion - ulpravda.ru
Certain Options of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-JAN-2026. - marketscreener.com
Certain Common Stock of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-JAN-2026. - MarketScreener
4D Molecular falls after early-stage trial data for cystic fibrosis therapy - MSN
Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely - Finviz
Ashoo Gupta of 4D Molecular Therapeutics sells $3.3k in FDMT stock - Investing.com Australia
4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) institutional investors lost 20% over the past week but have profited from longer-term gains - Yahoo Finance
4D Molecular Therapeutics Gains Momentum from Clinical Data and Index Inclusion - AD HOC NEWS
4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to S&P Biotechnology Select Industry Index - marketscreener.com
How interest rate cuts could boost 4D Molecular Therapeutics Inc. stockJuly 2025 Chart Watch & Accurate Buy Signal Notifications - Улправда
Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail
Is 4D Molecular Therapeutics Inc. stock ready for breakoutJuly 2025 Weekly Recap & Long Hold Capital Preservation Plans - Улправда
4D Molecular Therapeutics Executive Sells Shares - TradingView — Track All Markets
4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop (NASDAQ:FDMT) - Seeking Alpha
Analysts Are Bullish on Top Healthcare Stocks: Novan (NOVN), 4D Molecular Therapeutics (FDMT) - The Globe and Mail
What insider trading reveals about 4D Molecular Therapeutics Inc. stockQuarterly Portfolio Report & AI Powered Trade Plan Recommendations - DonanımHaber
Analysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Novan (NOVN) - The Globe and Mail
Stock Market Recap: Is 4D Molecular Therapeutics Inc. stock a top momentum playQuarterly Portfolio Report & Accurate Buy Signal Notifications - DonanımHaber
4D Molecular Therapeutics (NASDAQ:FDMT) Given “Buy” Rating at Chardan Capital - Defense World
Chardan Capital Maintains 4D Molecular Therapeutics (FDMT) Buy Recommendation - Nasdaq
What dividend safety score for 4D Molecular Therapeutics Inc. stockJuly 2025 Action & Long-Term Investment Growth Plans - Улправда
4D Molecular Therapeutics : 710 AEROW Interim Phase 1 Data & Program Update (610855) - marketscreener.com
4D Molecular posts Phase 1 trial data for cystic fibrosis drug - Seeking Alpha
4D Molecular Therapeutics Announces Positive Interim Clinical Data from 4D-710 Aerow Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease - marketscreener.com
4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform PotentialSlideshow (NASDAQ:FDMT) 2025-12-17 - Seeking Alpha
4D Molecular Therapeutics Reports Positive Interim Phase 1 Data For 4D-710 In Cystic Fibrosis - Nasdaq
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease - Yahoo Finance
Officer Bizily Files To Sell 1,635 Of 4D Molecular Therapeutics Inc [FDMT] - TradingView — Track All Markets
4D Molecular Therapeutics (FDMT) director reports 9,333-share option exercise - Stock Titan
4DMT Announces New Employment Inducement Grants - Sahm
4D Molecular Therapeutics (Nasdaq: FDMT) Issues 13,800 RSUs Under 2025 Inducement Plan - Stock Titan
4D Molecular Therapeutics expands phase 3 trial enrollment - MSN
4D Molecular Therapeutics grants CFO option on 480,000 FDMT shares | FDMT SEC FilingForm 4 - Stock Titan
4D Molecular Therapeutics (FDMT) CFO reports no securities holdings - Stock Titan
4D Molecular Therapeutics Expands Phase 3 Trial Enrollment - TipRanks
4D Molecular Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
4D Molecular Therapeutics Advances in Macular Degeneration Treatment: A Phase 3 Study Update - MSN
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Decheng Capital LLC - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 7.4%Here's What Happened - MarketBeat
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - MSN
4D Molecular Therapeutics Reports Strategic Gains in Q3 2025 - MSN
4D Molecular Therapeutics taps Kristian Humer as CFO - MSN
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
4D Molecular Therapeutics Appoints New Financial Officer - MSN
Finanzdaten der 4 D Molecular Therapeutics Inc-Aktie (FDMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
4.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):